Suvorexant — Membership Pricing

Other medications in Mental Health

• Temazepam
• Thioridazine
• Thiothixene
• Tranylcypromine
• Trazodone
• Triazolam
• Trifluoperazine
• Valproate

What Suvorexant is approved for (FDA label)

BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. BELSOMRA is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: March 10, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Suvorexant (FDA label)

5 mg tablets are yellow, round, film-coated tablets with "5" on one side and plain on the other side. 10 mg tablets are green, round, film-coated tablets with "33" on one side and plain on the other side. 15 mg tablets are white, oval, film-coated tablets with the corporate logo on one side and "325" on the other side. 20 mg tablets are white, round, film-coated tablets with the corporate logo and "335" on one side and plain on the other side. Tablets, 5 mg, 10 mg, 15 mg, 20 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: e5b72731-1acb-45b7-9c13-290ad12d3951. SPL document ID: 21306af5-e07a-4f8e-8f59-3e0aacc53102. Label effective date: March 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Suvorexant (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections: CNS Depressant Effects and Daytime Impairment [see Warnings and Precautions (5.1) ] Worsening of Depression/Suicidal Ideation [see Warnings and Precautions (5.2) ] Complex Sleep Behaviors [see Warnings and Precautions (5.3) ] Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, Cataplexy-Like Symptoms [see Warnings and Precautions (5.4) ] Patients with Compromised Respiratory Function [see Warnings and Precautions (5.5) ] The most common adverse reaction (reported in 5% or more of patients treated with BELSOMRA and at least twice the placebo rate) with BELSOMRA was somnolence ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: e5b72731-1acb-45b7-9c13-290ad12d3951. SPL document ID: 21306af5-e07a-4f8e-8f59-3e0aacc53102. Label effective date: March 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Suvorexant (FDA label)

BELSOMRA is contraindicated in patients with narcolepsy. BELSOMRA is contraindicated in patients with narcolepsy ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: e5b72731-1acb-45b7-9c13-290ad12d3951. SPL document ID: 21306af5-e07a-4f8e-8f59-3e0aacc53102. Label effective date: March 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Suvorexant (FDA label)

CNS Depressant Effects and Daytime Impairment: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness ( 5.1 ). Worsening of Depression/Suicidal Ideation: Worsening of depression or suicidal thinking may occur. Risk increases with dose. Immediately evaluate any new behavioral changes ( 5.2 ). Complex Sleep Behaviors: Behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur. Discontinue immediately if a complex sleep behavior occurs ( 5.3 ). Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms: May occur with the use of BELSOMRA. Risk increases with dose ( 5.4 ). Compromised Respiratory Function: Effect on respiratory function should be considered ( 5.5 , 8.6 ).

Source: FDA prescribing information (DailyMed). Set ID: e5b72731-1acb-45b7-9c13-290ad12d3951. SPL document ID: 21306af5-e07a-4f8e-8f59-3e0aacc53102. Label effective date: March 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Suvorexant (FDA label)

CYP3A inhibitors: Recommended dose is 5 mg when used with moderate CYP3A inhibitors. Dose can be increased to 10 mg once per night if the 5 mg dose is not effective. Not recommended for use in patients taking strong CYP3A inhibitors ( 2.4 , 7.2 ). Strong CYP3A inducers: Efficacy may be reduced ( 7.2 ). Digoxin: Monitor digoxin concentrations ( 7.3 ). 7.1 CNS-Active Agents When BELSOMRA was co-administered with alcohol, additive psychomotor impairment was demonstrated. There was no alteration in the pharmacokinetics of BELSOMRA [see Warnings and Precautions (5.1 , 5.3) and Clinical Pharmacology (12.3) ]. 7.2 Effects of Other Drugs on BELSOMRA Metabolism by CYP3A is the major elimination pathway for suvorexant.

Source: FDA prescribing information (DailyMed). Set ID: e5b72731-1acb-45b7-9c13-290ad12d3951. SPL document ID: 21306af5-e07a-4f8e-8f59-3e0aacc53102. Label effective date: March 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.